Research programme: metal-protein-attenuating compounds - Prana Biotechnology

Drug Profile

Research programme: metal-protein-attenuating compounds - Prana Biotechnology

Alternative Names: MPAC - Prana Biotechnology; PBT 519; PBT-434; PBT3 series - Prana Biotechnology; PBT4 series - Prana Biotechnology

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prana Biotechnology
  • Class Quinazolinones
  • Mechanism of Action Alpha-synuclein inhibitors; Dopamine modulators; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain cancer
  • Research Neurodegenerative disorders
  • No development reported Parkinson's disease
  • Discontinued Age-related macular degeneration; Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in Australia (PO)
  • 05 Jul 2017 Updated pharmacodynamics data from a preclinical trial in parkinson's disease released by Prana Biotechnology
  • 07 Jun 2017 Discontinued - Preclinical for Age-related macular degeneration in Australia (unspecified route) (Prana Biotechnology pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top